Literature DB >> 8583975

Pre-eclampsia, autoimmune diseases and breast cancer etiology.

A P Polednak1.   

Abstract

Previous hypotheses concerning the negative association between pre-eclampsia (or pregnancy-induced hypertension) and breast cancer risk have focused on hormone-related factors. A hypothesis is presented that certain non-specific cellular immune responses could be involved in this association and in the negative association between autoimmune diseases (i.e., systemic lupus erythematosus and rheumatoid arthritis) and certain cancers. Future directions for epidemiological and laboratory research suggested by this hypothesis are discussed.

Entities:  

Mesh：

Year:  1995        PMID： 8583975     DOI： 10.1016/0306-9877(95)90271-6

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN： 0306-9877            Impact factor:   1.538


  4 in total

1.  Gestational Hypertensive Disorders and Maternal Breast Cancer Risk in a Nationwide Cohort of 40,720 Parous Women.

Authors:  Mandy Goldberg; Mary V Díaz-Santana; Katie M O'Brien; Shanshan Zhao; Clarice R Weinberg; Dale P Sandler
Journal:  Epidemiology       Date:  2022-05-30       Impact factor: 4.860

2.  Pregnancy complications and subsequent breast cancer risk in the mother: a Nordic population-based case-control study.

Authors:  Rebecca Troisi; Anne Gulbech Ording; Tom Grotmol; Ingrid Glimelius; Anders Engeland; Mika Gissler; Britton Trabert; Anders Ekbom; Laura Madanat-Harjuoja; Henrik Toft Sørensen; Steinar Tretli; Tone Bjørge
Journal:  Int J Cancer       Date:  2018-08-10       Impact factor: 7.396

3.  Assessment of All-Cause Cancer Incidence Among Individuals With Preeclampsia or Eclampsia During First Pregnancy.

Authors:  Chris Serrand; Thibault Mura; Pascale Fabbro-Peray; Gilles Seni; Ève Mousty; Thierry Boudemaghe; Jean-Christophe Gris
Journal:  JAMA Netw Open       Date:  2021-06-01

4.  Preeclampsia and maternal breast cancer risk by offspring gender: do elevated androgen concentrations play a role?

Authors:  R Troisi; K E Innes; J M Roberts; R N Hoover
Journal:  Br J Cancer       Date:  2007-08-07       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.